Overview

Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis

Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
we will study the efficacy and safety of mirabegron25 in treatment of primary nocturnal enuresis in comparison to oral desmopressin 120 mcg and behavioral therapy
Phase:
N/A
Details
Lead Sponsor:
Benha University
Treatments:
Deamino Arginine Vasopressin
Mirabegron